TY - JOUR
TI - Apathy as a Treatment Target in Alzheimer's Disease: Implications for
Clinical Trials
AU - Mortby, Moyra E.
AU - Adler, Lawrence
AU - Aguera-Ortiz, Luis
AU - Bateman,
AU - Daniel R.
AU - Brodaty, Henry
AU - Cantillon, Marc
AU - Geda, Yonas E. and
AU - Ismail, Zahinoor
AU - Lanctot, Krista L.
AU - Marshall, Gad A.
AU - Padala,
AU - Prasad R.
AU - Politis, Antonios
AU - Rosenberg, Paul B.
AU - Siarkos,
AU - Kostas
AU - Sultzer, David L.
AU - Theleritis, Christos
AU - Pia, Istaart
AU - Nps
JO - American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry
PY - 2022
VL - 30
TODO - 2
SP - 119-147
PB - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN - 1064-7481, 1545-7214
TODO - 10.1016/j.jagp.2021.06.016
TODO - apathy; treatment target; neurocognitive disorders; assessment; future
directions; pre-dementia states; ISTAART neuropsychiatric; syndromes
professional interest area
TODO - Apathy is one of the most prevalent, stable and persistent
neuropsychiatric symptom across the neurocognitive disorders spectrum.
Recent advances in understanding of phenomenology, neurobiology and
intervention trials highlight apathy as an important target for clinical
intervention. We conducted a comprehensive review and critical
evaluation of recent advances to determine the evidence-based
suggestions for future trial designs. This review focused on 4 key
areas: 1) pre-dementia states; 2) assessment; 3) mechanisms/biomarkers
and 4) treatment/intervention efficacy. Considerable progress has been
made in understanding apathy as a treatment target and appreciating
pharmacological and non-pharmacological apathy treatment interventions.
Areas requiring greater investigation include: diagnostic procedures,
symptom measurement, understanding the biological mechanisms/biomarkers
of apathy, and a well formed approach to the development of treatment
strategies. A better under- standing of the subdomains and biological
mechanisms of apathy will advance apathy as a treatment target for
clinical trials. (Am J Geriatr Psychiatry 2022; 30:119-147)
ER -